China Traditional Chinese Medicine Holdings (00570) has announced its interim results for the six months ended June 30, 2026, revealing a significant deterioration in financial performance.

The company reported revenue of RMB 5.438 billion, a decline of 27.1% year-on-year. The net loss attributable to shareholders widened substantially to RMB 776 million, an increase of 619.3% compared to the same period last year. The basic loss per share stood at RMB 15.42 cents.

According to the company's announcement, the 27.1% drop in operating revenue during the reporting period was primarily driven by the Chinese herbal medicine formula granule business. This segment faced reduced terminal demand as a result of industry policy adjustments and shifts in the market environment, leading to lower sales volumes during the period.